MAPT and frontotemporal dementia: A recent report has shown that β-arrestin1 levels are increased in the brains of FTD patients, and β-arrestins are essential for the β2 adrenergic receptor and mGluR2 glutamate receptor-mediated increase in pathogenic tau (83).